Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.

Date publication

août 2015

Journal

The American journal of gastroenterology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Fréling E, Baumann C, Cuny JF, Bigard MA, Schmutz JL, Barbaud A, Peyrin-Biroulet L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26195181

Résumé

The broader and prolonged use of anti-tumor necrosis factor (TNF) agents in inflammatory bowel disease (IBD) could expose patients to an increased risk of adverse reactions, including dermatological complications. We assessed the cumulative incidence of anti-TNF-induced cutaneous adverse reactions in IBD patients, their risk factors, their dermatological management, and their outcome in a large cohort of IBD patients.

Mots clés

Adalimumab, Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal, administration & dosage, Antibodies, Monoclonal, administration & dosage, Antibodies, Monoclonal, Humanized, administration & dosage, Child, Colitis, Ulcerative, drug therapy, Crohn Disease, drug therapy, Dose-Response Relationship, Drug, Drug Eruptions, epidemiology, Female, Humans, Incidence, Infliximab, Kaplan-Meier Estimate, Male, Middle Aged, Prevalence, Proportional Hazards Models, Psoriasis, chemically induced, Retrospective Studies, Risk Factors, Skin Diseases, Infectious, chemically induced, Tumor Necrosis Factor-alpha, antagonists & inhibitors, Young Adult

Référence

Am. J. Gastroenterol.. 2015 Aug;110(8):1186-96